Sign in
Taking people in United StatesPhase 4

Using a tracer and probe to find meningioma tumor during surgery

Tests whether a tracer injection helps surgeons detect meningioma during surgery in adults.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Registry title
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Status
Recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
11 Sept 2024
Expected to end
Jan 2027
Type of study
Interventional
Treatments tested
  • Brain Imaging with [Cu64]DOTATATE
  • Radio-guided Surgery With Neoprobe Utilization
Record updated
27 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a likely or known meningioma (a tumour of the brain's covering) who need surgery. During surgery, a probe will look for the tumour after an injection of [Cu64]DOTATATE.

Age
18 Years to 99 Years
Sex
All sexes can join
Disease stage
Meningioma strongly suspected on MRI and needing surgery to remove it. Or meningioma confirmed after earlier surgery, with scans showing tumour that came back or remained and needs another surgery.
Earlier treatment
People who had radiation therapy to the head before cannot join.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Surgery through the nose, through an eyebrow cut, or any surgery where the neoprobe cannot be used
  • Allergy to somatostatin analogs
  • Cannot have a usual MRI
  • Currently in another treatment trial for meningioma

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery

Who cannot take part

  • Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
  • Patients with prior history of cranial radiation therapy
  • Patients with hypersensitivity to somatostatin analogs
  • Pregnant or breastfeeding
  • Patients with contraindications to conventional MRI
  • Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • New York - Presbyterian - Weill Cornell Medical CenterNew York, United StatesContact: Jana Ivanidze, MD/PhDTaking people

About the trial

What the trial wants to find out

The study team hypothesizes that it is feasible to intraoperatively detect tumor following [CU64]DOTATATE injection using the gamma probe device.

The group in the trial

  • Patients with MRI findings compatible with meningioma who have an indication for surgeryTreatment being tested

    A diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.

    Treatment: Brain Imaging with [Cu64]DOTATATE and Radio-guided Surgery With Neoprobe Utilization

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pilot Study to Evaluate Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Plain-language title
Using a tracer and probe to find meningioma tumor during surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06377371, who can take part
Record updated
27 February 2026